5 July 2021
DLA Piper advises Philip Morris International on USD820 million acquisition of Fertin Pharma
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Tom Heylen Lead | DLA Piper | Partner | Corporate | Not stated |
| Tim Baumgartner Lead | DLA Piper | Partner | Corporate | Not stated |
| Marco de Morpurgo Lead | DLA Piper | Partner | Intellectual Property and Technology | Not stated |
| Laura Marcelli | DLA Piper | Counsel | Corporate | Not stated |
| Miriam Gott | DLA Piper | Associate | Corporate | Not stated |
| Richard Taylor | DLA Piper | Partner | Intellectual Property and Technology | Not stated |
| Mark Dewar | DLA Piper | Partner | Intellectual Property and Technology | Not stated |
| Sarah Smith | DLA Piper | Partner | Antitrust | Not stated |
| Jeremy Sher | DLA Piper | Partner | Litigation | Not stated |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 820m (USD820 million)
- What the figure measures
- Enterprise value
- Client
- Philip Morris InternationalBuy-side
- Counterparties
- Fertin Pharma A/S (Target)
EQT (Sell-side)
Bagger-Sørensen & Co (Sell-side)